- Home
- USGO vs RCEL Comparison
USGO vs RCEL Comparison
Compare USGO & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USGO
- RCEL
- Stock Information
- Founded
- USGO 2015
- RCEL N/A
- Country
- USGO United States
- RCEL United States
- Employees
- USGO N/A
- RCEL N/A
- Industry
- USGO Precious Metals
- RCEL Medical/Dental Instruments
- Sector
- USGO Basic Materials
- RCEL Health Care
- Exchange
- USGO Nasdaq
- RCEL Nasdaq
- Market Cap
- USGO 117.3M
- RCEL 113.7M
- IPO Year
- USGO 2023
- RCEL N/A
- Fundamental
- Price
- USGO $9.38
- RCEL $6.25
- Analyst Decision
- USGO Strong Buy
- RCEL Strong Buy
- Analyst Count
- USGO 2
- RCEL 4
- Target Price
- USGO $26.50
- RCEL $13.75
- AVG Volume (30 Days)
- USGO 81.9K
- RCEL 1.2M
- Earning Date
- USGO 11-12-2025
- RCEL 11-06-2025
- Dividend Yield
- USGO N/A
- RCEL N/A
- EPS Growth
- USGO N/A
- RCEL N/A
- EPS
- USGO N/A
- RCEL N/A
- Revenue
- USGO N/A
- RCEL $74,884,000.00
- Revenue This Year
- USGO N/A
- RCEL $22.92
- Revenue Next Year
- USGO N/A
- RCEL $37.07
- P/E Ratio
- USGO N/A
- RCEL N/A
- Revenue Growth
- USGO N/A
- RCEL 38.32
- 52 Week Low
- USGO $5.65
- RCEL $3.60
- 52 Week High
- USGO $14.46
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- USGO 58.75
- RCEL 66.61
- Support Level
- USGO $8.82
- RCEL $4.12
- Resistance Level
- USGO $9.80
- RCEL $7.12
- Average True Range (ATR)
- USGO 0.59
- RCEL 0.35
- MACD
- USGO 0.06
- RCEL 0.25
- Stochastic Oscillator
- USGO 72.55
- RCEL 71.00
About USGO U.S. GoldMining Inc. Common stock
US Goldmining Inc is a mineral exploration and development company. It is focused on the exploration and development of a project located in Alaska, USA. The company's sole property is Whistler Project which is a gold-copper exploration project located in the Yentna Mining District, approximately 170 km northwest of Anchorage, Alaska.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.